產品詳情
簡單介紹：
Anti-CARD15抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-CARD15抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-CARD15
Cat. Number:
Anti-CARD15抗體KL-7084R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Defects in NOD2 are the cause of sarcoidosis early-onset (EOS) . EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs Anti-CARD15抗體may be involved. Early-onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement.
Also known as:
ACUG; Arthrocutaneouveal granulomatosis; BLAU; CARD15; Caspase recruitment domain protein 15; Caspase recruitmentAnti-CARD15抗體 domain-containing protein 15; CD; IBD1; Inflammatory bowel disease protein 1; LRR containing protein; LRR-containing protein; Nod2; NOD2 protein; NOD2_HUMAN; NOD2B; nucleotide binding oligomerization domain 2; nucleotide-binding oligomerization domain 2; Nucleotide-binding oligomerization domain-containing protein 2; PSORAS1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human CARD15.
●
Predicted Molecular Weight:Anti-CARD15抗體 114kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:50-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutionsAnti-CARD15抗體 must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutionsAnti-CARD15抗體 must be determined by the end user.
kl043Mu01 維甲酸X受體α(RXRα)多克隆抗體 Polyclonal Antibody to Retinoid X Receptor Alpha (RXRa)
kl043Mu02 維甲酸X受體α(RXRα)多克隆抗體 Polyclonal Antibody to Retinoid X Receptor Alpha (RXRa)
kl044Mu01 肝X受體α(LXRα)多克隆抗體 Polyclonal Antibody to Liver X Receptor Alpha (LXRa)
kl044Mu02 肝X受體α(LXRα)多克隆抗體 Polyclonal Antibody to Liver X Receptor Alpha (LXRa)
kl045Mu02 存活素(Surv)多克隆抗體 Polyclonal Antibody to Survivin (Surv)
kl046Mu01 S100鈣結合蛋白A10(S100A10)多克隆抗體 Polyclonal Antibody to S100 Calcium Binding Protein A10 (S100A10)
kl046Mu02 S100鈣結合蛋白A10(S100A10)多克隆抗體 Polyclonal Antibody to S100 Calcium Binding Protein A10 (S100A10)
kl047Mu02 Ki-67蛋白(Ki67P)多克隆抗體 Polyclonal Antibody to Ki-67 Protein (Ki67P)
kl056Mu02 基質金屬蛋白酶14(MMP14)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 14 (MMP14)
kl058Mu01 白介素20(IL20)多克隆抗體 Polyclonal Antibody to Interleukin 20 (IL20)
kl058Mu02 白介素20(IL20)多克隆抗體 Polyclonal Antibody to Interleukin 20 (IL20)
kl058Ra01 白介素20(IL20)多克隆抗體 Polyclonal Antibody to Interleukin 20 (IL20)
kl059Hu01 周期素依賴性激酶6(CDK6)多克隆抗體 Polyclonal Antibody to Cyclin Dependent Kinase 6 (CDK6)
kl064Mu02 白介素24(IL24)多克隆抗體 Polyclonal Antibody to Interleukin 24 (IL24)
kl068Mu01 VEGF共調節趨化因子1(VCC1)多克隆抗體 Polyclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1)
kl068Mu02 VEGF共調節趨化因子1(VCC1)多克隆抗體 Polyclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1)
kl068Ra01 VEGF共調節趨化因子1(VCC1)多克隆抗體 Polyclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1)
kl071Mu01 干擾素誘導T-細胞α亞族趨化劑(ITαC)多克隆抗體 Polyclonal Antibody to Interferon Inducible T-Cell Alpha Chemoattractant (ITaC)
kl071Mu02 干擾素誘導T-細胞α亞族趨化劑(ITαC)多克隆抗體 Polyclonal Antibody to Interferon Inducible T-Cell Alpha Chemoattractant (ITaC)
kl075Mu02 單核細胞趨化蛋白5(MCP5)多克隆抗體 Polyclonal Antibody to Monocyte Chemotactic Protein 5 (MCP5)
